BioSpace News Archive

MolecuLight i:X will Provide Essential Real-Time Information to Assist Wound Care Plus’s Advanced Wound Care Consultants in Providing the Highest Quality Wound Care

While the recent and rapid development of Pfizer/BioNTech’s COVID-19 vaccine is undoubtedly good news, Time Magazine reported that administering this vaccine to individuals with a history of severe allergic reactions is not recommended, according to a U.K.

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Apellis Pharmaceuticals Inc. (Nasdaq: APLS) today announced positive top-line results at week 48 from the phase 3 PEGASUS study, which demonstrated sustained haematological and clinical improvements in patients with paroxysmal nocturnal haemoglobinuria (PNH) who were treated with pegcetacoplan, an investigational, targeted C3 therapy.

Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the , a global innovator in drug delivery platforms, announces that it has closed the sale of its non-pharmaceutical THC-related assets held within Lexaria Canpharm ULC, a Lexaria wholly-owned subsidiary, to Hill Street Beverage Company Inc.

ReWalk Robotics, Ltd., a leading manufacturer of robotic medical devices for people with lower extremity disabilities, announced it has entered into a contract with a German private health insurance company to allow all eligible beneficiaries with spinal cord injury to apply for the procurement of a ReWalk 6.0 exoskeleton system.

A historic alliance of life sciences and healthcare organizations seeks to accelerate the broad adoption of patient-focused, decentralized clinical trials and research.

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”), a global leader in specialized, research-driven cannabis extraction, distillation and derivative products, today announced a senior leadership transition.

Mr. Ginsberg brings twenty-five years of rare disease corporate development, finance, strategy, and investment leadership experience.

CollPlant (NASDAQ: CLGN), a regenerative medicine company, and STEMCELL Technologies, Canada’s largest privately owned biotechnology company, which develops cell culture media, cell separation systems, instruments, and other reagents for life sciences research, today jointly announced they have entered into a product manufacturing and supply agreement.

ASPIVIX SA, a developer of medical technologies to advance gynecological care, today announced completion of and interim analysis results from its Phase I first-in-women trial.